Index -
P/E -
EPS (ttm) -
Insider Own 71.46%
Shs Outstand 19.11M
Perf Week -8.74%
Market Cap 139.69M
Forward P/E -
EPS next Y -
Insider Trans 11.48%
Shs Float 5.46M
Perf Month -15.00%
Income -
PEG -
EPS next Q -
Inst Own -
Short Float 0.14%
Perf Quarter -
Sales -
P/S -
EPS this Y -
Inst Trans -
Short Ratio 0.19
Perf Half Y -
Book/sh -5.64
P/B -
EPS next Y -
ROA -
Short Interest 0.01M
Perf Year -
Cash/sh 0.11
P/C 67.49
EPS next 5Y -
ROE -
52W Range 7.33 - 10.16
Perf YTD -15.10%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -
52W High -28.07%
Beta -
Dividend TTM -
Quick Ratio 0.15
Sales past 5Y 0.00%
Gross Margin -
52W Low -0.27%
ATR (14) 0.58
Dividend Ex-Date -
Current Ratio 0.15
EPS Y/Y TTM -
Oper. Margin -
RSI (14) -
Volatility 6.84% 4.70%
Employees -
Debt/Eq -
Sales Y/Y TTM -
Profit Margin -
Recom -
Target Price -
Option/Short No / Yes
LT Debt/Eq -
EPS Q/Q -
Payout -
Rel Volume 2.74
Prev Close 8.19
Sales Surprise -
EPS Surprise -
Sales Q/Q -
Earnings -
Avg Volume 40.07K
Price 7.31
SMA20 -9.69%
SMA50 -11.53%
SMA200 -11.53%
Trades
Volume 109,771
Change -10.74%
Sep-16-24 08:00AM
Sep-11-24 08:00AM
Sep-09-24 08:00AM
Sep-05-24 09:10AM
Aug-20-24 09:00AM
04:05PM
Loading…
Aug-14-24 04:05PM
Aug-12-24 08:27PM
May-28-24 07:00AM
Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
THOMSON TODD S 16.4% Owner Aug 14 '24 Sale 8.00 18,750 150,000 1,184,795 Aug 16 09:12 PM Bios Equity COF, LP Director Aug 14 '24 Buy 8.00 500,000 4,000,000 1,259,427 Aug 14 08:54 PM Bios Equity COF, LP Director Aug 14 '24 Sale 9.00 24,999 224,991 131,248 Aug 14 08:54 PM Fletcher Aaron G.L. Director Aug 14 '24 Buy 8.00 500,000 4,000,000 1,259,427 Aug 14 08:49 PM Fletcher Aaron G.L. Director Aug 14 '24 Sale 9.00 24,999 224,991 131,248 Aug 14 08:49 PM Kreis Leslie W. 10% Owner Aug 14 '24 Buy 8.00 500,000 4,000,000 1,259,427 Aug 14 08:44 PM Kreis Leslie W. 10% Owner Aug 14 '24 Sale 9.00 24,999 224,991 131,248 Aug 14 08:44 PM
Index -
P/E -
EPS (ttm) -1.65
Insider Own 25.54%
Shs Outstand 10.72M
Perf Week -0.75%
Market Cap 42.93M
Forward P/E -
EPS next Y -2.02
Insider Trans -1.08%
Shs Float 8.02M
Perf Month -10.14%
Income -17.75M
PEG -
EPS next Q -0.56
Inst Own 11.95%
Short Float 2.78%
Perf Quarter -3.86%
Sales 0.00M
P/S -
EPS this Y -44.22%
Inst Trans 0.92%
Short Ratio 3.93
Perf Half Y -55.81%
Book/sh 2.87
P/B 1.39
EPS next Y 4.72%
ROA -40.79%
Short Interest 0.22M
Perf Year 3.91%
Cash/sh 3.09
P/C 1.29
EPS next 5Y -
ROE -44.82%
52W Range 2.38 - 11.99
Perf YTD -6.78%
Dividend Est. -
P/FCF -
EPS past 5Y -39.81%
ROI -57.28%
52W High -66.72%
Beta 1.55
Dividend TTM -
Quick Ratio 7.67
Sales past 5Y 0.00%
Gross Margin -
52W Low 67.65%
ATR (14) 0.40
Dividend Ex-Date -
Current Ratio 7.67
EPS Y/Y TTM -25.30%
Oper. Margin 0.00%
RSI (14) 50.92
Volatility 10.24% 10.41%
Employees 21
Debt/Eq 0.01
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 26.00
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q -5.44%
Payout -
Rel Volume 0.90
Prev Close 4.07
Sales Surprise -
EPS Surprise 16.36%
Sales Q/Q -
Earnings Aug 08 AMC
Avg Volume 56.76K
Price 3.99
SMA20 1.97%
SMA50 -3.29%
SMA200 -21.55%
Trades
Volume 51,265
Change -1.97%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-07-21 Initiated
H.C. Wainwright
Buy
$32
Aug-31-24 02:02PM
Aug-08-24 04:01PM
Aug-07-24 09:31AM
Aug-05-24 08:00AM
Aug-01-24 08:00AM
08:30AM
Loading…
Jul-10-24 08:30AM
Jun-12-24 07:30AM
May-23-24 11:51AM
May-09-24 04:02PM
(Business Wire) +5.09%
-9.54%
May-06-24 06:41AM
(Pharmaceutical Technology) +11.38%
04:37AM
03:00AM
May-02-24 07:30AM
May-01-24 06:00AM
Apr-24-24 08:00AM
08:12AM
Loading…
Apr-22-24 08:12AM
Apr-10-24 08:45AM
Mar-20-24 09:00AM
Mar-19-24 09:06AM
Mar-18-24 08:53PM
05:32PM
04:02PM
Mar-15-24 08:00AM
Mar-11-24 07:30AM
Mar-07-24 06:17AM
Mar-05-24 08:01AM
Mar-04-24 08:01AM
Feb-20-24 08:01AM
Feb-15-24 08:01AM
Jan-17-24 07:30AM
08:05AM
Loading…
Dec-13-23 08:05AM
Nov-30-23 08:00AM
Nov-10-23 11:31AM
Nov-08-23 06:43PM
04:01PM
Nov-01-23 08:00AM
Oct-24-23 04:03PM
Oct-10-23 08:00AM
Oct-03-23 08:00AM
Sep-29-23 07:40AM
Sep-25-23 08:30AM
Sep-18-23 09:00AM
Sep-14-23 09:09AM
Aug-31-23 08:00AM
Aug-28-23 05:32PM
08:00AM
Aug-23-23 06:00PM
Aug-14-23 08:30AM
Aug-10-23 08:37AM
(Zacks Small Cap Research) +7.07%
Aug-09-23 04:01PM
09:11AM
Aug-08-23 03:06PM
Aug-02-23 12:45PM
08:00AM
Aug-01-23 07:30PM
Jul-30-23 02:45PM
Jul-17-23 08:00AM
Jun-26-23 08:30AM
Jun-12-23 08:30AM
Jun-08-23 09:00AM
May-19-23 06:50AM
May-17-23 08:00AM
May-10-23 09:59AM
(Zacks Small Cap Research)
May-09-23 04:01PM
May-03-23 09:00AM
May-02-23 04:01PM
07:30AM
Apr-13-23 07:30AM
Mar-28-23 08:00AM
Mar-24-23 07:15AM
Mar-22-23 11:50AM
11:45AM
(Zacks Small Cap Research)
Mar-21-23 04:01PM
12:11PM
(Thomson Reuters StreetEvents)
Mar-20-23 04:01PM
Mar-15-23 08:00AM
Mar-13-23 08:00AM
06:16AM
06:00AM
Mar-09-23 08:00AM
Mar-08-23 08:00AM
Mar-06-23 08:00AM
Mar-02-23 08:00AM
Feb-27-23 08:00AM
Feb-21-23 12:10PM
Feb-15-23 08:00AM
Feb-01-23 04:55AM
(Zacks Small Cap Research)
Jan-17-23 08:00AM
Jan-05-23 08:59AM
Dec-31-22 06:15AM
Dec-15-22 08:00AM
Dec-13-22 08:00AM
Dec-02-22 01:46PM
08:00AM
Nov-22-22 08:00AM
Nov-08-22 04:48AM
(Zacks Small Cap Research)
Nov-07-22 04:01PM
Nov-02-22 08:00AM
Oct-31-22 08:00AM
Oct-25-22 08:00AM
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Fletcher Aaron G.L. 10% Owner May 24 '24 Sale 6.33 20,000 126,600 57,467 May 28 04:30 PM Fletcher Aaron G.L. 10% Owner May 23 '24 Sale 6.25 10,000 62,500 59,326 May 28 04:30 PM Fletcher Aaron G.L. 10% Owner Feb 28 '24 Sale 4.85 74,297 360,340 62,088 Feb 29 09:54 PM Fletcher Aaron G.L. 10% Owner Feb 27 '24 Sale 4.40 50,000 220,000 68,997 Feb 29 09:54 PM Fletcher Aaron G.L. 10% Owner Feb 29 '24 Sale 4.87 19,703 95,954 60,256 Feb 29 09:54 PM Kreis Leslie W. 10% Owner Feb 28 '24 Sale 4.85 74,297 360,340 62,088 Feb 29 09:54 PM Kreis Leslie W. 10% Owner Feb 27 '24 Sale 4.40 50,000 220,000 68,997 Feb 29 09:54 PM Kreis Leslie W. 10% Owner Feb 29 '24 Sale 4.87 19,703 95,954 60,256 Feb 29 09:54 PM Fletcher Aaron G.L. 10% Owner Jan 17 '24 Sale 4.20 58,889 247,334 73,646 Jan 19 04:31 PM Kreis Leslie W. 10% Owner Jan 17 '24 Sale 4.20 58,889 247,334 73,646 Jan 19 04:30 PM Fletcher Aaron G.L. 10% Owner Nov 29 '23 Sale 3.44 145,348 499,997 217,553 Dec 01 06:01 AM Kreis Leslie W. 10% Owner Nov 29 '23 Sale 3.44 145,348 499,997 217,553 Dec 01 06:00 AM
Index -
P/E -
EPS (ttm) -18.00
Insider Own 2.66%
Shs Outstand 7.63M
Perf Week -5.17%
Market Cap 4.20M
Forward P/E -
EPS next Y -0.72
Insider Trans 30.64%
Shs Float 7.42M
Perf Month -18.28%
Income -9.96M
PEG -
EPS next Q -0.41
Inst Own 0.78%
Short Float 2.81%
Perf Quarter -86.54%
Sales 0.41M
P/S 10.24
EPS this Y 95.89%
Inst Trans -
Short Ratio 0.07
Perf Half Y -91.89%
Book/sh 1.80
P/B 0.31
EPS next Y 68.07%
ROA -145.30%
Short Interest 0.21M
Perf Year -99.05%
Cash/sh 0.10
P/C 5.25
EPS next 5Y -
ROE -222.30%
52W Range 0.49 - 68.40
Perf YTD -98.01%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -465.41%
52W High -99.20%
Beta -1.87
Dividend TTM -
Quick Ratio 0.74
Sales past 5Y 149.87%
Gross Margin -10.21%
52W Low 11.79%
ATR (14) 0.14
Dividend Ex-Date -
Current Ratio 0.74
EPS Y/Y TTM -
Oper. Margin -2497.68%
RSI (14) 38.64
Volatility 11.65% 9.26%
Employees 10
Debt/Eq 0.42
Sales Y/Y TTM -
Profit Margin -2440.46%
Recom 1.00
Target Price 3.50
Option/Short No / Yes
LT Debt/Eq 0.24
EPS Q/Q 78.21%
Payout -
Rel Volume 0.13
Prev Close 0.60
Sales Surprise -
EPS Surprise -5.59%
Sales Q/Q -95.64%
Earnings Aug 12 AMC
Avg Volume 2.87M
Price 0.55
SMA20 -11.19%
SMA50 -46.30%
SMA200 -95.50%
Trades
Volume 372,095
Change -8.18%
Sep-18-24 09:00AM
Sep-06-24 04:30PM
Aug-28-24 08:30AM
Aug-22-24 09:00AM
Aug-20-24 04:15PM
06:23PM
Loading…
Aug-12-24 06:23PM
Jul-25-24 05:57PM
Jul-23-24 09:20PM
(Business Wire) +206.79%
-76.46%
08:00AM
Jun-27-24 04:05PM
(Business Wire) +12.72%
-30.15%
May-31-24 08:00AM
May-17-24 08:00AM
May-10-24 08:00AM
May-09-24 05:00PM
Apr-22-24 04:30PM
04:15PM
Loading…
Apr-18-24 04:15PM
Mar-15-24 04:15PM
Feb-16-24 04:05PM
(Business Wire) +6.01%
+5.79%
Feb-13-24 10:09PM
(Business Wire) -24.33%
-73.91%
Jan-16-24 09:00AM
Jan-03-24 09:00AM
Nov-14-23 04:30PM
Oct-16-23 08:00AM
Aug-29-23 08:00AM
Aug-14-23 04:05PM
Jul-19-23 04:05PM
Jul-11-23 04:05PM
Jun-21-23 06:46PM
Jun-15-23 07:04PM
Azitra, Inc. is an early-stage clinical biopharmaceutical company, which engages in the development of therapeutic use in dermatology. The firm is involved in using engineered proteins and live bio therapeutic products that can be applied topically to treat diseases of the skin. It also offers a platform which is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen library of strains for drug like molecules. The company was founded by Azim Munivar and Travis Whitfill on January 2, 2014 and is headquartered in Branford, CT.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
KDT VENTURES FUND I, LP Former Director Sep 13 '24 Proposed Sale 0.58 9,730 5,648 Sep 16 05:47 PM Staskey Norm Chief Financial Officer Mar 29 '24 Buy 0.21 47,600 10,034 51,100 Apr 01 09:51 PM Whitfill Travis Chief Operating Officer Feb 13 '24 Buy 0.30 15,000 4,500 334,500 Feb 15 08:42 PM Staskey Norm Chief Financial Officer Feb 13 '24 Buy 0.30 3,300 990 3,500 Feb 15 08:39 PM Salva Francisco D. President and CEO Feb 13 '24 Buy 0.30 333,300 99,990 338,300 Feb 15 08:38 PM
Index -
P/E -
EPS (ttm) -0.83
Insider Own 30.33%
Shs Outstand 43.29M
Perf Week -0.70%
Market Cap 14.71M
Forward P/E -
EPS next Y -0.53
Insider Trans 0.00%
Shs Float 32.59M
Perf Month -42.05%
Income -31.96M
PEG -
EPS next Q -0.15
Inst Own 22.47%
Short Float 0.61%
Perf Quarter -64.64%
Sales 0.00M
P/S -
EPS this Y 37.50%
Inst Trans -21.13%
Short Ratio 0.78
Perf Half Y -74.86%
Book/sh 0.29
P/B 1.07
EPS next Y 14.67%
ROA -122.41%
Short Interest 0.20M
Perf Year -72.91%
Cash/sh 0.22
P/C 1.44
EPS next 5Y -
ROE -180.45%
52W Range 0.28 - 2.48
Perf YTD -77.22%
Dividend Est. -
P/FCF -
EPS past 5Y -50.62%
ROI -180.18%
52W High -87.33%
Beta -0.01
Dividend TTM -
Quick Ratio 2.66
Sales past 5Y 0.00%
Gross Margin -
52W Low 11.81%
ATR (14) 0.04
Dividend Ex-Date -
Current Ratio 2.66
EPS Y/Y TTM 32.89%
Oper. Margin 0.00%
RSI (14) 27.03
Volatility 7.84% 11.17%
Employees 31
Debt/Eq 0.43
Sales Y/Y TTM -
Profit Margin -
Recom 1.40
Target Price 6.83
Option/Short No / Yes
LT Debt/Eq 0.30
EPS Q/Q 29.45%
Payout -
Rel Volume 0.31
Prev Close 0.32
Sales Surprise -
EPS Surprise -9.64%
Sales Q/Q -
Earnings Aug 08 AMC
Avg Volume 255.04K
Price 0.31
SMA20 -22.12%
SMA50 -48.99%
SMA200 -69.56%
Trades
Volume 79,611
Change -2.12%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-18-24 Initiated
Laidlaw
Buy
$7.50
Aug-30-22 Initiated
H.C. Wainwright
Buy
$14
Sep-05-24 08:33AM
(Pharmaceutical Technology) -27.33%
Sep-04-24 04:01PM
Aug-29-24 06:05AM
Aug-12-24 08:05AM
Aug-08-24 04:05PM
08:00AM
Loading…
Jun-24-24 08:00AM
Jun-14-24 02:04PM
Jun-13-24 04:01PM
Jun-03-24 06:05AM
May-24-24 08:00AM
May-23-24 05:00PM
May-14-24 10:00AM
May-13-24 08:00AM
May-09-24 10:57PM
04:00PM
06:05AM
Loading…
Apr-30-24 06:05AM
Apr-24-24 08:00AM
Apr-16-24 04:05PM
Apr-09-24 04:30PM
Mar-14-24 09:54PM
04:00PM
Mar-05-24 04:30PM
Feb-26-24 08:00AM
Feb-14-24 08:00AM
Jan-04-24 08:00AM
Dec-11-23 04:05PM
(GlobeNewswire) +29.29%
+27.73%
09:00AM
Dec-07-23 08:00AM
Dec-05-23 08:00AM
Nov-20-23 07:00AM
07:00AM
Loading…
Nov-10-23 07:00AM
Nov-09-23 04:00PM
Nov-06-23 08:00AM
Nov-03-23 12:00PM
Nov-02-23 09:17AM
Nov-01-23 08:00AM
Oct-12-23 08:00AM
Sep-29-23 08:00AM
Sep-26-23 08:00AM
Sep-20-23 08:00AM
Sep-19-23 08:03AM
Sep-06-23 08:00AM
Aug-15-23 08:00AM
Aug-10-23 04:15PM
Aug-08-23 08:00AM
Jun-05-23 08:00AM
May-17-23 08:00AM
May-12-23 08:00AM
May-02-23 05:08PM
(GlobeNewswire) +21.84%
+11.32%
May-01-23 08:00AM
Apr-26-23 10:00AM
Apr-25-23 08:00AM
Apr-24-23 08:00AM
Apr-17-23 09:00AM
Apr-11-23 08:00AM
Mar-30-23 04:15PM
Mar-16-23 08:00AM
Mar-01-23 08:00AM
Feb-23-23 07:00AM
Feb-21-23 07:00AM
Jan-17-23 07:00AM
Jan-05-23 07:00AM
Jan-03-23 07:00AM
Dec-12-22 07:00AM
Dec-08-22 07:00AM
Nov-10-22 07:30AM
Nov-03-22 09:10AM
Nov-01-22 07:30AM
Sep-27-22 07:30AM
Sep-15-22 07:30AM
Sep-13-22 07:30AM
Sep-08-22 07:30AM
Aug-30-22 04:15PM
(GlobeNewswire) +39.39%
-6.16%
Aug-19-22 09:20AM
Aug-16-22 04:15PM
Aug-12-22 04:15PM
Aug-11-22 10:05PM
Jul-27-22 07:00AM
Jul-21-22 07:00AM
Jul-12-22 08:00AM
Jul-10-22 09:12AM
Jun-30-22 04:15PM
Jun-08-22 08:00AM
Jun-06-22 07:00AM
May-17-22 07:00AM
May-12-22 08:00AM
May-05-22 08:00AM
May-04-22 08:00AM
May-03-22 11:00AM
(Simply Wall St.) +11.11%
Apr-13-22 08:30AM
Apr-05-22 04:15PM
Mar-28-22 08:00AM
Mar-17-22 04:15PM
Mar-04-22 07:00AM
Feb-10-22 05:36PM
Jan-31-22 12:29PM
(Simply Wall St.) +12.33%
Jan-10-22 07:00AM
Jan-06-22 07:00AM
Dec-16-21 07:00AM
Dec-09-21 04:30PM
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
Index -
P/E -
EPS (ttm) -0.93
Insider Own 15.78%
Shs Outstand 40.13M
Perf Week -3.42%
Market Cap 23.26M
Forward P/E -
EPS next Y -0.78
Insider Trans 0.00%
Shs Float 33.80M
Perf Month -22.70%
Income -31.08M
PEG -
EPS next Q -0.20
Inst Own 13.31%
Short Float 2.71%
Perf Quarter -69.49%
Sales 0.00M
P/S -
EPS this Y 4.07%
Inst Trans -0.77%
Short Ratio 0.93
Perf Half Y -69.33%
Book/sh 0.57
P/B 1.01
EPS next Y 6.06%
ROA -79.36%
Short Interest 0.91M
Perf Year -53.63%
Cash/sh 0.71
P/C 0.82
EPS next 5Y -
ROE -108.31%
52W Range 0.54 - 2.95
Perf YTD -68.67%
Dividend Est. -
P/FCF -
EPS past 5Y -21.09%
ROI -132.55%
52W High -80.35%
Beta 1.39
Dividend TTM -
Quick Ratio 3.07
Sales past 5Y 0.00%
Gross Margin -
52W Low 6.94%
ATR (14) 0.06
Dividend Ex-Date -
Current Ratio 3.07
EPS Y/Y TTM -11.41%
Oper. Margin 0.00%
RSI (14) 33.24
Volatility 4.36% 6.29%
Employees 28
Debt/Eq 0.03
Sales Y/Y TTM -
Profit Margin -
Recom 1.33
Target Price 7.50
Option/Short No / Yes
LT Debt/Eq 0.02
EPS Q/Q -10.15%
Payout -
Rel Volume 0.20
Prev Close 0.61
Sales Surprise -
EPS Surprise 23.63%
Sales Q/Q -
Earnings Aug 08 BMO
Avg Volume 989.04K
Price 0.58
SMA20 -9.79%
SMA50 -41.71%
SMA200 -66.61%
Trades
Volume 202,262
Change -4.89%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-30-24 Downgrade
Cantor Fitzgerald
Overweight → Neutral
Nov-03-21 Initiated
Oppenheimer
Outperform
$22
Nov-03-21 Initiated
B. Riley Securities
Buy
$27
Sep-03-24 07:30AM
Aug-22-24 07:31AM
Aug-08-24 07:00AM
Aug-05-24 07:30AM
Jul-30-24 06:32AM
(Clinical Trials Arena) -17.29%
11:58AM
Loading…
Jul-29-24 11:58AM
07:00AM
Jul-26-24 04:11PM
Jul-02-24 07:30AM
May-21-24 07:30AM
May-07-24 01:53PM
07:30AM
Apr-29-24 07:30AM
Apr-22-24 07:30AM
Apr-02-24 07:30AM
07:30AM
Loading…
Apr-01-24 07:30AM
Mar-27-24 09:31AM
01:13AM
(Thomson Reuters StreetEvents)
Mar-26-24 11:53AM
07:00AM
Mar-15-24 07:30AM
Mar-14-24 04:05PM
Mar-11-24 08:16PM
04:05PM
Mar-06-24 07:30AM
Feb-26-24 07:30AM
Feb-06-24 08:47AM
Jan-04-24 07:30AM
Nov-16-23 07:30AM
Nov-15-23 07:30AM
07:30AM
Loading…
Nov-07-23 07:30AM
Nov-03-23 06:00AM
Nov-02-23 07:30AM
Oct-27-23 07:30AM
Oct-24-23 04:30PM
Oct-16-23 07:30AM
Sep-07-23 07:45AM
Aug-30-23 08:00AM
Aug-09-23 09:09AM
Aug-08-23 09:52PM
(Thomson Reuters StreetEvents)
07:00AM
Aug-02-23 07:30AM
Jul-11-23 07:30AM
Jul-05-23 07:30AM
Jun-28-23 07:00AM
Jun-27-23 07:17PM
Jun-20-23 07:30AM
Jun-02-23 07:30AM
May-23-23 09:40AM
07:30AM
May-18-23 03:53PM
07:30AM
May-04-23 04:05PM
May-01-23 07:30AM
Apr-19-23 07:30AM
Apr-12-23 07:30AM
Mar-28-23 07:30AM
Mar-27-23 08:00AM
07:12AM
Mar-23-23 11:03PM
(Thomson Reuters StreetEvents)
+6.01%
07:30AM
Mar-21-23 08:00AM
Mar-16-23 12:18PM
07:30AM
Mar-15-23 07:30AM
Mar-07-23 08:00AM
Feb-22-23 08:00AM
Feb-21-23 07:30AM
Feb-20-23 08:50AM
Feb-09-23 08:00AM
Dec-22-22 08:00AM
Dec-21-22 04:05PM
Dec-15-22 08:00AM
Dec-01-22 08:38AM
(Simply Wall St.) -25.93%
07:30AM
Nov-28-22 08:00AM
Nov-21-22 08:00AM
Nov-15-22 12:55PM
Nov-14-22 08:00AM
Nov-10-22 08:00AM
Oct-12-22 08:00AM
Oct-11-22 08:00AM
Sep-29-22 07:30AM
Sep-27-22 07:32AM
Sep-06-22 07:32AM
Aug-11-22 06:56AM
Aug-09-22 07:00AM
Aug-04-22 04:02PM
(GlobeNewswire) +62.16%
-13.06%
02:30PM
Aug-03-22 04:05PM
Jul-19-22 08:00AM
Jun-23-22 07:30AM
Jun-08-22 07:30AM
Jun-02-22 04:01PM
May-13-22 07:30AM
May-11-22 07:00AM
May-04-22 05:54PM
04:01PM
May-03-22 08:00AM
May-02-22 11:18AM
(Simply Wall St.) +13.36%
Cognition Therapeutics, Inc. is a clinical stage neuroscience company which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer's disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Ricciardi Lisa CEO & President Mar 14 '24 Buy 1.75 5,700 9,975 291,345 Mar 14 04:34 PM
Index -
P/E -
EPS (ttm) -7.96
Insider Own 10.44%
Shs Outstand 3.47M
Perf Week 4.52%
Market Cap 8.02M
Forward P/E -
EPS next Y -3.77
Insider Trans 0.00%
Shs Float 3.10M
Perf Month 11.06%
Income -19.39M
PEG -
EPS next Q -0.81
Inst Own 18.70%
Short Float 4.52%
Perf Quarter 32.76%
Sales 0.00M
P/S -
EPS this Y 63.88%
Inst Trans 8.35%
Short Ratio 3.36
Perf Half Y -71.86%
Book/sh 1.81
P/B 1.28
EPS next Y 11.92%
ROA -168.10%
Short Interest 0.14M
Perf Year -72.46%
Cash/sh 1.27
P/C 1.83
EPS next 5Y -
ROE -213.51%
52W Range 1.35 - 11.00
Perf YTD -67.09%
Dividend Est. -
P/FCF -
EPS past 5Y -13.86%
ROI -329.84%
52W High -79.00%
Beta 1.36
Dividend TTM -
Quick Ratio 1.63
Sales past 5Y 0.00%
Gross Margin -
52W Low 71.11%
ATR (14) 0.26
Dividend Ex-Date -
Current Ratio 1.63
EPS Y/Y TTM 61.32%
Oper. Margin 0.00%
RSI (14) 58.31
Volatility 12.64% 14.82%
Employees 19
Debt/Eq 0.01
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 30.00
Option/Short No / Yes
LT Debt/Eq 0.00
EPS Q/Q 64.78%
Payout -
Rel Volume 1.29
Prev Close 2.31
Sales Surprise 333.47%
EPS Surprise 28.24%
Sales Q/Q -
Earnings Aug 14 AMC
Avg Volume 41.79K
Price 2.31
SMA20 8.68%
SMA50 17.11%
SMA200 -44.35%
Trades
Volume 53,982
Change 0.00%
Date
Action
Analyst
Rating Change
Price Target Change
May-19-22 Resumed
H.C. Wainwright
Buy
$22
Feb-08-21 Initiated
H.C. Wainwright
Buy
$31
Dec-07-20 Initiated
B. Riley Securities
Buy
$36
Aug-17-20 Reiterated
Maxim Group
Buy
$12 → $18
Jul-08-20 Initiated
Maxim Group
Buy
$12
Sep-11-24 07:00AM
Sep-10-24 07:00AM
Sep-03-24 08:00AM
Aug-14-24 09:54PM
05:20PM
04:05PM
Loading…
04:05PM
Aug-06-24 08:00AM
Jun-26-24 07:00AM
Jun-24-24 07:00AM
Jun-19-24 06:00AM
May-23-24 07:00AM
May-20-24 11:37AM
07:00AM
May-15-24 07:00AM
May-14-24 10:54PM
06:00PM
Loading…
06:00PM
04:05PM
May-01-24 05:07PM
Apr-30-24 05:53AM
Apr-29-24 08:00PM
10:00AM
Apr-15-24 07:00AM
Mar-28-24 10:54PM
(InvestorPlace) -8.35%
+6.13%
04:05PM
Mar-27-24 04:01PM
Mar-25-24 09:01AM
Mar-22-24 03:11PM
Mar-20-24 12:00PM
09:03AM
Mar-14-24 04:47PM
08:00AM
Loading…
Jan-24-24 08:00AM
Jan-09-24 08:00AM
Dec-20-23 10:52AM
10:52AM
Dec-19-23 06:00AM
Dec-18-23 04:01PM
Dec-15-23 07:00AM
Dec-13-23 08:00AM
Nov-30-23 08:00AM
08:00AM
Nov-27-23 07:00AM
Nov-16-23 08:37AM
Nov-14-23 04:05PM
Nov-08-23 04:05PM
Nov-07-23 04:05PM
Oct-02-23 05:00PM
Sep-28-23 04:29PM
Aug-23-23 07:00AM
Aug-17-23 04:01PM
06:36AM
Aug-16-23 04:25AM
(Thomson Reuters StreetEvents) -9.76%
Aug-15-23 06:05AM
06:00AM
Aug-14-23 04:01PM
Aug-09-23 08:30AM
Aug-08-23 05:50PM
Jul-31-23 07:00AM
Jun-26-23 07:00AM
May-23-23 04:05PM
May-11-23 04:05PM
May-09-23 07:15AM
May-04-23 08:00AM
May-01-23 07:00AM
Apr-08-23 08:58AM
Mar-07-23 04:15PM
Mar-06-23 04:05PM
Feb-23-23 01:01PM
Feb-08-23 04:05PM
Jan-09-23 08:00AM
Dec-05-22 06:30AM
Nov-29-22 04:01PM
Nov-21-22 01:40PM
Nov-18-22 08:00AM
Nov-17-22 04:01PM
05:34AM
Nov-14-22 04:01PM
(GlobeNewswire) -12.43%
-18.92%
Nov-07-22 04:05PM
Nov-03-22 08:00AM
Nov-02-22 12:47PM
Nov-01-22 04:07PM
04:05PM
Oct-18-22 10:23AM
Oct-11-22 08:00AM
Sep-26-22 08:00AM
Sep-22-22 08:00AM
Sep-08-22 08:00AM
Sep-06-22 08:00AM
Aug-12-22 11:30AM
Aug-11-22 04:05PM
Aug-02-22 04:05PM
Jul-14-22 08:00AM
Jun-24-22 03:44PM
Jun-09-22 08:00AM
Jun-01-22 08:00AM
May-31-22 09:55AM
May-20-22 09:32AM
May-11-22 05:15PM
04:01PM
May-10-22 03:34PM
May-02-22 08:00AM
TFF Pharmaceuticals, Inc. engages in the development and commercialization of drug products based on its patented Thin Film Freezing technology platform. It focuses on the manufacture of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company was founded on January 24, 2018 and is headquartered in Fort Worth, TX.
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite